PMID- 1541981
OWN - NLM
STAT- MEDLINE
DCOM- 19920409
LR  - 20190907
IS  - 0167-594X (Print)
IS  - 0167-594X (Linking)
VI  - 12
IP  - 1
DP  - 1992 Jan
TI  - Treatment of recurrent malignant glioma by repeated intracerebral injections of 
      human recombinant interleukin-2 alone or in combination with systemic 
      interferon-alpha. Results of a phase I clinical trial.
PG  - 75-83
AB  - Nine patients with a recurrent malignant glioma were treated with repeated 
      intracavitary or intracerebroventricular injections of human recombinant 
      interleukin-2 (rIL-2) alone or in combination with systemic interferon-alpha 
      (IFN-alpha). Five patients received only rIL-2 and four were treated with rIL-2 
      plus subcutaneous injections of IFN-alpha. Therapy was administered on a Monday, 
      Wednesday, Friday schedule for up to 10 weeks, beginning with a dose of 10,000 IU 
      rIL-2/injection. Doses were escalated every two weeks until some toxicity was 
      apparent. The maximum amount of rIL-2 any one patient in this group received was 
      580,000 IU. Patients on combination immunotherapy were held at an rIL-2 dosage of 
      10,000 IU while IFN-alpha, which began at 3 million IU, was escalated every other 
      week up to 18 million IU/dose. They were then held at that IFN-alpha dosage and 
      rIL-2 was increased to 50,000 IU. The total amount of rIL-2 and IFN-alpha any one 
      in this group received was 510,000 IU and 417 million IU, respectively. Repeated 
      injections of 10,000 IU rIL-2 were well-tolerated by all nine patients and no 
      change in their functional status was seen. At doses at 50,000 IU rIL-2, 
      increased edema around the tumor cavity was observed by MRI/CT scand in 3/5 
      patients and clinical side-effects in the form of somnolence and headache along 
      with some morbidity specifically associated with tumor location were also seen. 
      Patients receiving rIL-2+ IFN-alpha showed progressive fatigue, muscle weakness, 
      and occasionally nausea. Two of these patients showed increased peritumoral edema 
      on MRI/CT scan.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Merchant, R E
AU  - Merchant RE
AD  - Department of Surgery, Medical College of Virginia, Virginia Commonwealth 
      University, Richmond.
FAU - McVicar, D W
AU  - McVicar DW
FAU - Merchant, L H
AU  - Merchant LH
FAU - Young, H F
AU  - Young HF
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Interferon Type I)
RN  - 0 (Interleukin-2)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Adult
MH  - Brain Neoplasms/diagnostic imaging/surgery/*therapy
MH  - Drug Administration Schedule
MH  - Drug Evaluation
MH  - Female
MH  - Glioma/diagnostic imaging/surgery/*therapy
MH  - Humans
MH  - Injections
MH  - Injections, Intraventricular
MH  - Interferon Type I/administration & dosage/*therapeutic use/toxicity
MH  - Interleukin-2/administration & dosage/*therapeutic use/toxicity
MH  - Male
MH  - Neoplasm Recurrence, Local
MH  - Recombinant Proteins/therapeutic use/toxicity
MH  - Tomography, X-Ray Computed
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
AID - 10.1007/BF00172459 [doi]
PST - ppublish
SO  - J Neurooncol. 1992 Jan;12(1):75-83. doi: 10.1007/BF00172459.